Natixis Buys Shares of 213,900 Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Natixis bought a new stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 213,900 shares of the biopharmaceutical company’s stock, valued at approximately $8,977,000. Natixis owned approximately 0.32% of Celldex Therapeutics at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. BNP Paribas Financial Markets lifted its holdings in Celldex Therapeutics by 48.9% in the 4th quarter. BNP Paribas Financial Markets now owns 136,601 shares of the biopharmaceutical company’s stock valued at $5,418,000 after purchasing an additional 44,878 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Celldex Therapeutics by 16.3% during the 4th quarter. Vanguard Group Inc. now owns 3,046,331 shares of the biopharmaceutical company’s stock valued at $120,817,000 after acquiring an additional 427,827 shares during the last quarter. Point72 Asset Management L.P. increased its stake in shares of Celldex Therapeutics by 105.3% during the 4th quarter. Point72 Asset Management L.P. now owns 2,756,122 shares of the biopharmaceutical company’s stock valued at $109,308,000 after acquiring an additional 1,413,722 shares during the last quarter. Charles Schwab Investment Management Inc. increased its stake in shares of Celldex Therapeutics by 13.2% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 409,391 shares of the biopharmaceutical company’s stock valued at $16,236,000 after acquiring an additional 47,844 shares during the last quarter. Finally, Affinity Asset Advisors LLC increased its stake in shares of Celldex Therapeutics by 166.7% during the 4th quarter. Affinity Asset Advisors LLC now owns 400,000 shares of the biopharmaceutical company’s stock valued at $15,864,000 after acquiring an additional 250,000 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on CLDX. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $67.00 price objective on shares of Celldex Therapeutics in a research note on Tuesday, June 18th. Wolfe Research began coverage on shares of Celldex Therapeutics in a research note on Tuesday, June 11th. They set an “outperform” rating and a $51.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and set a $80.00 price objective on shares of Celldex Therapeutics in a research note on Tuesday, July 16th. Finally, Stifel Nicolaus began coverage on shares of Celldex Therapeutics in a research report on Tuesday, June 18th. They set a “buy” rating and a $58.00 target price for the company. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, Celldex Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $62.17.

Celldex Therapeutics Stock Performance

CLDX traded up $4.55 on Thursday, reaching $43.86. 1,054,130 shares of the company’s stock were exchanged, compared to its average volume of 781,966. The company’s 50 day moving average is $36.45 and its 200-day moving average is $39.13. The company has a market cap of $2.89 billion, a price-to-earnings ratio of -14.82 and a beta of 1.58. Celldex Therapeutics, Inc. has a twelve month low of $22.11 and a twelve month high of $53.18.

Celldex Therapeutics (NASDAQ:CLDX) last posted its earnings results on Monday, May 6th. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.11. Celldex Therapeutics had a negative net margin of 2,385.57% and a negative return on equity of 29.55%. The firm had revenue of $0.16 million during the quarter, compared to the consensus estimate of $1.30 million. Sell-side analysts forecast that Celldex Therapeutics, Inc. will post -2.39 EPS for the current year.

Insider Buying and Selling at Celldex Therapeutics

In other Celldex Therapeutics news, VP Elizabeth Crowley sold 15,000 shares of the stock in a transaction that occurred on Friday, June 7th. The shares were sold at an average price of $35.06, for a total value of $525,900.00. Following the completion of the sale, the vice president now owns 9,074 shares of the company’s stock, valued at $318,134.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Celldex Therapeutics news, VP Elizabeth Crowley sold 15,000 shares of the stock in a transaction that occurred on Friday, June 7th. The shares were sold at an average price of $35.06, for a total value of $525,900.00. Following the completion of the sale, the vice president now owns 9,074 shares of the company’s stock, valued at $318,134.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Samuel Bates Martin sold 35,000 shares of the stock in a transaction that occurred on Thursday, May 30th. The shares were sold at an average price of $34.05, for a total transaction of $1,191,750.00. Following the completion of the sale, the chief financial officer now directly owns 25,128 shares of the company’s stock, valued at approximately $855,608.40. The disclosure for this sale can be found here. Insiders sold 266,332 shares of company stock valued at $9,155,821 over the last 90 days. 3.80% of the stock is owned by corporate insiders.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.